MEDROXYPROGESTERONE ACETATE
Generic: MEDROXYPROGESTERONE ACETATE
Amphastar PharmaceuticalsManufacturer
INTRAMUSCULARRoute
MEDROXYPROGESTERONE ACETATEActive Substance
2017-11-28Original Approval
MEDROXYPROGESTERONE ACETATE is FDA application ANDA077334, sponsored by AMPHASTAR PHARMS INC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2022-05-06
medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL, Rx only, Manufactured by Sun Lack of assurance of sterility
Class II2024-12-18
medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: CGMP Deviations
Top Reported Reactions
1
BREAST CANCER FEMALE
2,993 reports
2
BREAST CANCER
1,819 reports
3
MENINGIOMA
844 reports
4
BREAST CANCER METASTATIC
434 reports
5
DRUG INEFFECTIVE
309 reports
6
OFF LABEL USE
234 reports
7
OESTROGEN RECEPTOR ASSAY POSITIVE
215 reports
8
PAIN
200 reports
9
OVARIAN CANCER
186 reports
10
NAUSEA
182 reports